51 related articles for article (PubMed ID: 17161351)
1. Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver Transplantation and Impact on Outcomes.
Bittermann T; Lewis JD; Goldberg DS
Transplantation; 2022 Nov; 106(11):2182-2192. PubMed ID: 35706103
[TBL] [Abstract][Full Text] [Related]
2. Belatacept based immunosuppression: What and when to combine?
Schilsky J; Dvorai RH; Yang C; Suo L; Saracino G; Shahbazov R
Transpl Immunol; 2024 May; 85():102050. PubMed ID: 38810889
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and Management of CKD in the Nonkidney Solid Organ Transplant Recipient.
Warburton KM; Doyle AM
Clin J Am Soc Nephrol; 2018 Apr; 13(4):652-654. PubMed ID: 29326305
[No Abstract] [Full Text] [Related]
4. Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy.
Hwang S; Song GW; Jung DH; Park GC; Ahn CS; Moon DB; Ha TY; Kim KH; Lee SG
Ann Hepatobiliary Pancreat Surg; 2017 Feb; 21(1):11-16. PubMed ID: 28317040
[TBL] [Abstract][Full Text] [Related]
5. Analysis of adult 20-year survivors after liver transplantation.
Dopazo C; Bilbao I; Castells LL; Sapisochin G; Moreiras C; Campos-Varela I; Echeverri J; Caralt M; Lázaro JL; Charco R
Hepatol Int; 2015 Jul; 9(3):461-70. PubMed ID: 25788182
[TBL] [Abstract][Full Text] [Related]
6. Clinical mycophenolic acid monitoring in liver transplant recipients.
Chen H; Chen B
World J Gastroenterol; 2014 Aug; 20(31):10715-28. PubMed ID: 25152575
[TBL] [Abstract][Full Text] [Related]
7. A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.
Goralczyk AD; Schnitzbauer A; Tsui TY; Ramadori G; Lorf T; Obed A
BMC Surg; 2010 Apr; 10():15. PubMed ID: 20380712
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin-inhibitor-sparing immunosuppressive protocols.
Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
[TBL] [Abstract][Full Text] [Related]
12. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
[TBL] [Abstract][Full Text] [Related]
15. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.
Kornberg A; Küpper B; Thrum K; Krause B; Büchler P; Kornberg J; Sappler A; Altendorf-Hofmann A; Wilberg J; Friess H
Dig Dis Sci; 2011 Jan; 56(1):244-51. PubMed ID: 20824504
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
